Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 3/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.35 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29314737 | 0.91 | TLR7 (0.43) | ADORA3ADORA2ATLR8TLR7MAP4K4 | |
| SCHEMBL29314742 | 0.87 | TLR8 (0.36) | NOS1TLR8TLR7MAP4K4NOS3 | |
| SCHEMBL29314736 | 0.86 | TLR7 (0.36) | ADORA3ADORA2AAPPTLR8TLR7 | |
| SCHEMBL29321163 | 0.84 | ROCK1 (0.38) | ADORA3ADORA2AAPPTLR8TLR7 | |
| SCHEMBL29314687 | 0.83 | NAMPT (0.39) | ADORA3ADORA2ATLR8TLR7MAP4K4 | |
| SCHEMBL23037575 | 0.83 | TLR8 (0.41) | ADORA3ADORA2ANOS1TLR8TLR7 | |
| SCHEMBL30539889 | 0.83 | TLR8 (0.41) | ADORA3ADORA2ANOS1TLR8TLR7 | |
| SCHEMBL29314743 | 0.83 | TLR8 (0.39) | ADORA3ADORA2ANOS1TLR8TLR7 | |
| SCHEMBL29314557 | 0.82 | TLR8 (0.41) | ADORA3ADORA2ATLR8TLR7MAP4K4 | |
| SCHEMBL23037637 | 0.81 | TLR8 (0.43) | ADORA3ADORA2ATLR8TLR7ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | ADORA3 956/4885ADORA2A 459/4885NOS1 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.